Standard BioTools Inc. Disposal Group, Including Discontinued Operation, Revenue
Standard BioTools Inc. (LAB) reported Disposal Group, Including Discontinued Operation, Revenue of -$29.29 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Income Statement › Other Income
us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue · last filed 2026-08-05
- Standard BioTools Inc. disposal group, including discontinued operation, revenue for the quarter ending 2026-06-30 was $0.00.
- Standard BioTools Inc. disposal group, including discontinued operation, revenue for the quarter ending 2026-03-31 was -$29.29M.
- Standard BioTools Inc. disposal group, including discontinued operation, revenue for the quarter ending 2025-12-31 was -$606.00K.
- Standard BioTools Inc. disposal group, including discontinued operation, revenue for fiscal 2025 was -$727.00K.
| Period end | Disposal Group, Including Discontinued Operation, Revenue 3 month | Disposal Group, Including Discontinued Operation, Revenue 6 month | Disposal Group, Including Discontinued Operation, Revenue 9 month | Disposal Group, Including Discontinued Operation, Revenue 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | -$29.29M 10-Q · filed 2026-08-05 | -$29.89M derived: sum of 3 quarters · filed 2026-08-05 | |
| 2026-03-31 | -$29.29M 10-Q · filed 2026-05-06 | -$29.89M derived: sum of 2 quarters · filed 2026-05-06 | ||
| 2025-12-31 | -$606.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | -$727.00K 10-K · filed 2026-03-16 | ||
| 2025-09-30 | -$121.00K 10-Q · filed 2025-11-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |